During a session at the Academy of Managed Care Pharmacy’s (AMCP) Managed Care & Specialty Pharmacy Annual Meeting, held April 23-26 in Boston, Massachusetts, Reginia Benjamin, BS, JD, director of legislative affairs for AMCP, provided an in-depth look at state legislation on biosimilars.
During a session at the Academy of Managed Care Pharmacy’s (AMCP) Managed Care & Specialty Pharmacy Annual Meeting, held April 23-26 in Boston, Massachusetts, Reginia Benjamin, BS, JD, director of legislative affairs for AMCP, provided an in-depth look at state legislation on biosimilars.
Currently, 41 states and Puerto Rico have laws addressing biosimilars and interchangeable biosimilars, and 4 states still have bills pending, according to Benjamin. While there are 5 states that do not have biosimilar laws on the books, there is anticipation that 2 of those states will have a bill by 2019.
State legislation on biosimilars first arose in 2013, with 5 states taking the lead in developing and approving bills: Florida, North Dakota, Oregon, Utah, and Virginia. Three of the states—Utah, Oregon, and Virginia—had sunset provisions on their bills, meaning the bill would expire at the set date unless it was reenacted. All 3 bills would have expired before the first biosimilar was approved and introduced into the market, but they were reenacted by the states. By the time the first biosimilar was approved in 2015, 10 states had enacted biosimilar laws.
Benjamin then gave an overview of state legislative activity over the years. In 2013, the first biosimilar legislation required that the pharmacist notify the prescriber by either phone or fax within a specified period of time if they were going to dispense a biosimilar. There were also labeling requirements and additional record keeping that were not required for any other drug dispensed, according to Benjamin.
In 2014, new laws added provisions that notification could be achieved by adding a note into an electronic health record, so pharmacists would no longer have to phone or fax. In 2015, an entry into a pharmacy benefit manager’s system that was accessible to the prescriber was deemed as achieved notification, and in 2016, notification and labeling requirements arose for dispensing an interchangeable biosimilar. According to Benjamin, no additional provisions were added in 2017 or thus far in 2018.
Benjamin highlighted the fact that states do not use the FDA’s definition of interchangeable biosimilars. Instead, they refer to language in the Biologics Price Competition and Innovation Act (BPCIA), which references the standards of interchangeability.
State laws have also given interchangeability a 2-part definition: A biological product determined by the FDA to meet the standards of interchangeability set forth in the BPCIA, or a biological product determined by the FDA to be therapeutically equivalent as set forth by the FDA’s Orange Book—despite the fact that the Orange Book addresses small-molecule drugs and not biologics.
Additional state legislative language, which is not uniform, includes the following:
Benjamin finished up the presentation by outlining issues and challenges with current state legislation:
“It’s essential that we continue to provide patients, pharmacists, prescribers, and decision makers with educational resources to better inform them of the potential for these drugs to provide increased access to safe and more cost-effective drugs,” concluded Benjamin.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.